Compositions and methods relating to proliferative diseases

Provided are oral compositions comprising leelamine, a leelamine derivative of general formula (1), abietylamine, an abietylamine derivative of general formula (2) or (4), and/or an abietic acid derivative of general formula (3). The variables of the general formulae are as defined in the specification. Leelamine is also known as [(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methanamine, abietylamine is also known as { [(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-lyl]methyl} amine and abietic acid is also known as (1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylic acid. The compositions are useful for the treatment of cancer.